ASAP1 Promotes Epithelial to Mesenchymal Transition by Activating the TGFβ Pathway in Papillary Thyroid Cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Papillary thyroid cancer (PTC) is the most common thyroid cancer.
• While often treatable, some PTC cases are aggressive, leading to metastasis.
• The role of ASAP1 (ArfGAP with SH3, ankyrin repeats, and PH domain 1) in PTC metastasis is not well understood.

Purpose of the Study:

• To investigate the role of ASAP1 in papillary thyroid cancer progression.
• To explore the molecular mechanisms by which ASAP1 influences PTC metastasis.
• To assess the therapeutic potential of targeting ASAP1 in PTC.

Main Methods:

• ASAP1 expression analysis in PTC using TCGA and GEO databases.
• In vitro studies using PTC cell lines with ASAP1 knockdown or overexpression.
• Assessment of epithelial-mesenchymal transition (EMT) markers, cell proliferation, and invasion.
• Analysis of TGFβ pathway activity and ASAP1-SMAD2/3 interactions.

Main Results:

• ASAP1 is significantly upregulated in PTC tissues.
• ASAP1 knockdown suppressed EMT, proliferation, migration, and invasion in PTC cells.
• ASAP1 overexpression reversed these inhibitory effects.
• ASAP1 interacts with SMAD2/3, creating a positive feedback loop with TGFβ signaling, promoting EMT and invasiveness.

Conclusions:

• ASAP1 plays a crucial role in promoting PTC metastasis by driving EMT and activating the TGFβ pathway.
• Targeting ASAP1 presents a potential novel therapeutic strategy for aggressive PTC.
• Inhibition of ASAP1 may limit PTC spread by suppressing EMT and TGFβ signaling.